Home > Dermatology > PFGC 2021 > Best of the Posters > Potential biomarker discovered for treatment response to ustekinumab

Potential biomarker discovered for treatment response to ustekinumab

Presented By
Mr Shane Solanky, King’s College London, UK
PFGC 2021
Investigation of blood immune cells found that IL-23 induced signal transducer and activator of transcription (STAT)3 nuclear translocation in mucosal-associated invariant T (MAIT) cells could serve as a biomarker of treatment response to ustekinumab. If further validated, this may offer future guidance for ustekinumab therapy. Finding blood biomarkers able of predicting clinical response to systemic treatment of psoriasis is an emerging field of research. To evaluate whether or not STAT3 activation in IL-23 responsive cells could be a candidate for prediction, participants were enrolled from the Psoriasis Stratification to Optimise Relevant Therapy (PSORT) consortium [1]. IL-23-induced STAT3 translocation was determined by imaging flow cytometry of peripheral blood mononuclear cells (PBMCs) and quantified. PBMCs were collected from the participants at baseline and during treatment with ustekinumab at weeks 1, 4, and 12. The study cohort consisted o...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on